Skip to main
NYXH

Nyxoah SA (NYXH) Stock Forecast & Price Target

Nyxoah SA (NYXH) Analyst Ratings

Based on 3 analyst ratings
Buy
Strong Buy 0%
Buy 67%
Hold 33%
Sell 0%
Strong Sell 0%

Bulls say

Nyxoah is positioned for strong future growth with its successful U.S. commercial launch, as indicated by the positive leading indicators for new account adds and patient funnel development. Management's disciplined cost control and upcoming results from the ACCCESS study are additional catalysts for potential expansion and increased market share throughout 2026 and 2027. Despite potential risks such as competition from market leader Inspire Medical Systems and the need for additional capital, the overall outlook for Nyxoah is positive.

Bears say

Nyxoah is a highly innovative and promising company within the sleep-disordered breathing market, with its lead solution, the Genio system, showing potential for treating moderate to severe OSA. However, despite the company's recent upward guidance for FY26 revenue, there are concerns about its projected profitability, as management has guided for lower gross margins and higher operating expenses. Also, the company's decline in valuation multiple in the medtech sector raises questions about its long-term growth potential.

Nyxoah SA (NYXH) has been analyzed by 3 analysts, with a consensus rating of Buy. 0% of analysts recommend a Strong Buy, 67% recommend Buy, 33% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Nyxoah SA and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Nyxoah SA (NYXH) Forecast

Analysts have given Nyxoah SA (NYXH) a Buy based on their latest research and market trends.

According to 3 analysts, Nyxoah SA (NYXH) has a Buy consensus rating as of Aug 9, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $6.67, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $6.67, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Nyxoah SA (NYXH)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.